ME Therapeutics Holdings, Inc.

As of May 31, 2026, ME Therapeutics Holdings, Inc. carries a market capitalization of 51.69M, placing it among publicly traded companies globally. Its enterprise value stands at 51.18M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, ME Therapeutics Holdings, Inc. has 30.05M shares outstanding.

These figures are as of May 31, 2026.

As of May 31, 2026, ME Therapeutics Holdings, Inc. maintains a current ratio of 3.91, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.18, indicating elevated leverage, while an interest coverage ratio of -179.29 demonstrates limited ability to service its debt obligations.

Over the twelve months ended May 31, 2026, ME Therapeutics Holdings, Inc. posted a negative return on equity (ROE) of -111.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -98.27, reflecting losses generated across the asset base.

As of the close on October 21, 2026, ME Therapeutics Holdings, Inc.'s stock has declined approximately 82.18% over the past 52 weeks. The 50-day moving average sits at 2.35, while the 200-day moving average is 5.02.

Over the twelve months ended May 31, 2026, ME Therapeutics Holdings, Inc. generated - - in revenue and converted that into -1.38M in net income, yielding earnings per share of -0.05. EBITDA reached -1.45M, while operating income came in at -1.40M.

As of May 31, 2026, ME Therapeutics Holdings, Inc. holds 536,518.00 in cash and equivalents against 26,956.00 in total debt, resulting in a net debt position of -479,018.00. Total book value stands at 645,097.00, with working capital of 438,776.00 providing operational flexibility.

ME Therapeutics Holdings, Inc. produced -1.21M in operating cash flow over the twelve months ended May 31, 2026. After subtracting -75,817.00 in capital expenditures, free cash flow totaled -1.29M - equivalent to -0.04 per share.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield is negative at -2.51: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.23, meaning ME Therapeutics Holdings, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of May 31, 2026, ME Therapeutics Holdings, Inc. has an Altman Z-Score of 183.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.